COMMUNIQUÉS West-GlobeNewswire

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
23/10/2026
Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones [...]
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
23/10/2026
82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib Vopimetostat [...]
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
23/10/2026
PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, [...]
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
23/10/2026
HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory HQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two [...]
KFSH Marks Four Decades of Cardiac Innovation, from One Cath Lab to an Integrated Heart Center
23/10/2026
RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- What began with a single cardiac catheterization laboratory four decades ago has evolved into an advanced cardiovascular program at King Faisal Specialist Hospital [...]
Treace to Report Third Quarter 2026 Financial Results on November 6, 2026
23/10/2026
PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Super Vision Technology: World’s first i-NYS implant for congenital nystagmus in a Chinese boy
23/10/2026
BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- A 9-year-old boy has become the world's first patient to receive a newly approved implant to treat congenital nystagmus, in a procedure performed at Peking University People's [...]
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse
23/10/2026
Approval is based on Phase 3 results demonstrating significant progression-free and overall survival benefits, with teclistamab reducing risk of disease progression or death by 71% and risk of death by 40%, compared [...]
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
23/10/2026
Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone 1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints 1-3 Patients off Kisqali for a [...]
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
23/10/2026
Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated with progression-free survival and overall survival following immunotherapies including the [...]
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
23/10/2026
Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with [...]
Avacta Highlights pre|CISION® Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103)
23/10/2026
Preclinical data demonstrate tumor response with AVA6103 in the setting of Enhertu ® -resistance Potential for prolonged responses with increased FAP+ fibroblasts recruited to the tumor during treatment with AVA6103 [...]
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
23/10/2026
EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients with advanced [...]
Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer
23/10/2026
Faster and higher expansion of tumor-targeting CD8 T cells associated with longer overall survival in previously treated mismatch repair proficient (pMMR) metastatic colorectal cancer EO4010 was well tolerated and [...]
KFSH Cuts the Wait for an Echocardiography Appointment from 126 Days to One
23/10/2026
RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has reduced the wait for the first available echocardiography appointment at its Heart Center of [...]
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
23/10/2026
Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor [...]
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
23/10/2026
In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed [...]
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
23/10/2026
FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea
23/10/2026
Pratteln, Switzerland, October 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that its licensing partner Nxera Pharma Co., Ltd. (“Nxera”) has submitted a Marketing Authorization Application (MAA) to South [...]

Pages